You are here

AN IN VITRO INVESTIGATION OF SUITABILITY OF PRESS-COATED TABLETS WITH HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE (HPMCAS) AND SODIUM ALGINATE IN OUTER SHELL FOR COLON TARGETING.

Journal Name:

Publication Year:

Abstract (2. Language): 
The aim of present study was to develop a new colon targeting formulation, which can minimize the escape of Mesalazine completely in upper gastro ensure availability of maximum amount of drug to achieve the desired site i.e. distal colon. The use of press coated tablets with Hydroxypropylmethylcellulose acetate succinate (HPMCAS) and sodium alginate in outer shell was investigated. Two coats (upper and lower) were compressed onto the core tablets of Mesalazine using varying quantities of coating composition i.e. 100mg and 150mg each for lower and upper coat. The Mesalazine tablets coated by compressing 100 mg of HPMCAS each as upper and lower coat did not maintain integrity of the coats and released almost 100% of drug within 3 hrs. The tablets coated by compressing 150 mg of HPMCAS on the core tablets maintained good integrity during the dissolution test and prevented escape of Mesalazine totally in acid stage and buffer sage 1. However, the release of Mesalazine in subsequent buffer stage 2 was also affected. blends of HPMCAS and sodium alginate could maintain good mechanical strength in acid stage and buffer stage 1 and released 81.65 % of drug within 5 hrs. While the tablets with higher proportion of Sodium alginate in coat although possessed good mechanical strength indicated slower release of drug. The amount of Mesalazine released from the tablets coated with higher proportion of HPMCAS alone was comparable to that released from the tablets coated w sensitive polymers. These release indicating the usefulness of press coated tablets.
FULL TEXT (PDF): 
219-234

REFERENCES

References: 

1. Frieri G, Pimpo M and Galletti B: Longterm
oral plus topical mesalazine in
frequently relapsing ulcerative colitis.
Digestive and Liver Disease 2007; 37: 92-96.
2. Shanahan F: Probiotics in inflammatory
bowel disease- therapeutic rational and
role. Advance Drug Delivery Reviews 2004;
56: 809-818.
3. Rudolph MW, Klein S and Beckert ET: A
new 5 aminosalicylic acid multiunite dosage
form for the therapy of ulcerative colitis.
Eur J Pharm and biopharm 2001; 51: 183-
190
4. Fukui E, Miyamura N and Kobayashi M:
An vitro investigation of suitability if presscoated
tablets with (HPMCAS) and
Hydrophobic additives in outer shell for
colon targeting. Journal of Controlled
Release. 2001; 70: 97-107.
5. Fukui E, Miyamura N, Yoneyama T and
Kobayashi M: Drug release from and
mechanical properties of press coated
tablets with hydroxypropylmethylcellulose
acetate succinate and plasticizers in outer
shell. Int J Pharm. 2001; 217: 33–43.
6. Fukui E, Miyamura N, Uemura K and
Kobayashi M: Preparation of enteric coated
timed-release press-coated tablets and
evaluation of their function by in vitro and
in vivo tests for colon targeting. Int J Pharm.
2000; 204: 7–15.
7. Lieberman H.A., Lachman L. and Kanig
J.L.: The theory and practice of industrial
pharmacy, 3rd ed. Bombay: Verghese
publishing house.1990; 184.
8. The United state Pharmacopoeia, 27th
revision and the national formulary 22nd
edition. Vol.2 The official compendia of
standards, Asian edition published by the
board of trustees 2004; 1165.
9. Schellekens RCA, Stuurman FE and Van
der Weert FHJ: A novel dissolution method
relevant to intestinal release behaviour and
its application in the evaluation of modified
release mesalazine product. Eur J Pharm Sci
2007; 30: 15-20.
10. Aultons ME: 1998. Pharmaceutics: The
science of dosage form design.2nd ed.
London, England: Churchill Livingstone, 208.
Research Article ISSN: 2277-8713
Krishnakumar Devrao Lone, IJPRBS, 2013; Volume 2(1): 219-234 IJPRBS
Available Online At www.ijprbs.com
11. Sinha VR and Kumria R: Binders for
colon specific drug delivery: an in vitro

Thank you for copying data from http://www.arastirmax.com